Furthermore, we discuss the possibility and feasibility of utilizing CLR-mediated anti-fungal immunity as a novel effective target for synergizing and optimizing the efficacy of immune-checkpoint blockade therapy in bladder cancer. This evidence concerns the gene DCLK3 and urinary bladder carcinoma.